Detailed program
The program consists of keynotes and lectures by invited scientists, oral presentations based on selected submitted abstracts, as well as poster presentations.
To submit an abstract for oral presentation in the plenary sessions, please create an account and then log in with the supplied password. For further details, please see the information for presenters.
The program is preliminary as of December 1, 2017 and is subject to change.
Monday 4 December |
|
| 13.00 | Welcome |
| 13.15 | Session 1 - Computational cancer genomics Chair: Eivind Hovig |
| 13.15 | Keynote: Peter J. Park, Harvard Medical School Structural alternations in cancer genomes |
| 14.00 | Break |
| 14.20 | Keynote: Ivo Gut, Centro Nacional de Análisis Genómico (CNAG) The Pancancer study of the International Cancer Genome Consortium |
| 15.10 | Stian Knappskog, University of Bergen Driver mutations in chemoresistant breast cancer |
| 15.35 | Rolf Skotheim, OUS, The Norwegian Radium hospital Tumor heterogeneity in prostate cancer by multi-level genomics |
| 15.55 | Break |
| 16.15 | Keynote: Nitzan Rosenfeld, University of Cambridge Liquid biopsies: expanding technologies and clinical applications of circulating tumour DNA |
| 16.50 | Ola Myklebost, University of Bergen Using genomics and cell biology to find new treatment for orphan cancer |
| 17.15 | Thomas Berg, University Hospital of Northern-Norway Lessons from routine clinical pathology: Implementation of deep sequencing in the diagnostics of lung, melanoma and gastrointestinal malignancies |
| 17.30 | Break |
| 18.30 | City Hall Reception |
| 20.00 | End |
Tuesday 5 December |
|
| 09.00 | Session 2 - Personalized Cancer Detection, Tumour Immunology and the microenvironment Chair: June Myklebust |
| 09.00 | Keynote: Ash Alizadeh, Stanford University Circulating Tumor DNA Analysis for Personalized Cancer Detection and Monitoring |
| 09.45 | Break |
| 10.05 | Günter Schmidt, Definiens AG Discovery of novel predictive immune signatures using tissue phenomics |
| 10.40 | Els Verdegaal, Leiden University Medical Center Neoepitope dynamics during T cell therapy |
| 11.05 | June Myklebust, OUS, The Norwegian Radium Hospital Identification of targets for immune checkpoint blockade in B-cell lymphoma |
| 11.25 | Break |
| 11.45 | Randi Hovland, Haukeland University Hospital Clonal hematopoiesis in donor cells developed into acute myeloid leukemia in the recipient after allogenic stem cell transplantation |
| 12.05 | Jorrit Enserink, OUS, The Norwegian Radium Hospital Targeting the rewired protein interaction network of FLT3-ITD eradicates leukemic stem cells and overcomes FLT3 inhibitor resistance |
| 12.25 | Junbai Wang OUS, The Norwegian Radium Hospital Whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma |
| 12.45 | Thomas Fleischer OUS, The Norwegian Radium Hospital DNA methylation at enhancers identifies distinct breast cancer lineages and features of therapy response |
| 13.00 | Lunch |
| 14.15 | Session 3 - Single cell analysis for disease trajectories and Liquid Biopsies, monitoring cancer genetics in body fluids Chair: Leonardo Meza-Zepeda |
| 14.15 | Sten Eirik W. Jacobsen, University of Oxford Unraveling the biology of normal and malignant hematopoietic stem cells at the single cell level |
| 14.50 | Heidi Namløs, OUS, The Norwegian Radium Hospital Liquid biopsies; A non-invasive insight into the sarcoma genome |
| 15.15 | Break |
| 15.50 | Hilde Langseth, Cancer Registry of Norway Serum RNAs as biomarkers of Cancer |
| 16.15 | Trine B. Rounge, Cancer Registry of Norway Hypervariability in human papilloma virus - a cancer biomarker? |
| 16.30 | Poster session (with drinks/snacks) |
| 19.00 | Conference dinner |
Wednesday 6 December |
|
| 09.00 | Session 4 - Clinical interpretation to guide precision medicine and diagnostics (translation and clinical genomics). Precision drugs, reality, predictions and combinations and New strategies for “personalized” clinical trials Chair: Gunnar Sæter |
| 09.00 | Keynote: Ching C. Lau, Connecticut children's medical center Development and practice of precision medicine in pediatric oncology |
| 09.45 | Break |
| 10.00 | Edwin Cuppen, Hartwig medical foundation National scale tumor whole genome sequencing for personalized cancer treatment |
| 10.40 | Gunhild Mælandsmo, OUS, The Norwegian Radium hospital MetAction: Actionable Targets in Cancer Metastasis Experiences from the First Norwegian Study of NGS-Based Therapy Decisions in Advanced Cancer |
| 11.20 | Mev Dominguez Valentin, OUS, The Norwegian Radium Hospital Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds |
| 11.40 | Geir Hetland, OUS / University of Oslo The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse |
| 11.55 | Closing Remarks |
